Compare Amgen, Inc. (AMGN) vs Bank of America Corp (BAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Bank of America Corp — how do they compare? Amgen, Inc. trades at $356.51 (market cap $196.12B), while Bank of America Corp trades at $59.07 (market cap $423.45B). The key difference: Bank of America Corp is far larger — about 2.2× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BAC | |
|---|---|---|
Market Cap | $196.12B | $423.45B |
Sector | Health | Financials |
52-Week High | $388.16 | $59.90 |
52-Week Low | $271.18 | $44.92 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.88% |
Volume | — | 55,637,172 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Bank of America (BAC) trades at $59.67, up 0.71% today, with a bullish technical signal and strong analyst support. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $1.11 exceeding the $1.01 forecast. Revenue grew to $113.10 billion in 2025, and the company maintains a robust deposit base, positioning it for sustained earnings growth. A dividend of $0.28 per share is scheduled for payment on June 26, 2026.
The outlook for BAC is positive, driven by earnings momentum, favorable regulatory tailwinds, and a strong deposit franchise. Key risks include interest rate sensitivity and macroeconomic pressures. With 64.82% of analysts rating it a Buy and a consensus price target of $63.79, the stock offers potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
